Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth in Women Presenting With Signs and Symptoms of Preterm Labor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

165 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-01

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently, the American College of Obstetricians and Gynecologists (ACOG) indicate in their most recent Practice Bulletin on the Management of Preterm Labor that many tests to identify women at risk of preterm birth have been proposed and evaluated; however, only ultrasonography and fetal fibronectin testing have been shown to have benefit. Ultrasonography to determine cervical length, fetal fibronectin testing, or a combination of both may be useful in determining which women are at high risk for preterm delivery. However, their clinical usefulness may rest primarily with their ability to identify women who are least likely to deliver (i.e. their negative predictive value). Therefore, there is an urgent need for a test with a high positive predictive value in order to accurately predict imminent delivery to allow for salutary intervention.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth

NCT02092688

Preterm Labour Preterm Birth

COMPLETED

Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes

NCT00700219

Intra-amniotic Infection

UNKNOWN

Protein and Ultrasound Indicators of Preterm Birth

NCT01412931

Preterm Birth

COMPLETED

Interest of a Vaginal Swab in Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth

NCT03401255

Preterm Labor Preterm Birth

COMPLETED

Diagnostic Tests in the Context of Threatened Preterm Labour

NCT03608995

Preterm Labor Immunochromatographic Assay Predictive Value of Tests +2 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Birth

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PartoSure

Use of PartoSure to determine the risk of preterm birth

Group Type ACTIVE_COMPARATOR

PartoSure

Intervention Type DEVICE

Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1

Fetal Fibronectine (fFn)

Use of fFn to determine the risk of preterm birth

Group Type ACTIVE_COMPARATOR

Fetal Fibronectine

Intervention Type DEVICE

Diagnostic Kit for the Detection of Fetal Fibronectine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PartoSure

Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1

Intervention Type DEVICE

Fetal Fibronectine

Diagnostic Kit for the Detection of Fetal Fibronectine

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients presenting for emergency obstetrical care at an emergency room or labor \& delivery unit with signs, symptoms or complaints suggestive of preterm labor (PTL)

* Uterine contractions, with or without pain
* Intermittent lower abdominal pain
* Dull backache
* Pelvic pressure
* Bleeding during the second or third trimester
* Menstrual-like or intestinal cramping, with or without diarrhea
* Patient is not "feeling right"
* Gestational age between 200/7 and 366/7
* Consenting to be part of the trial

Exclusion Criteria

* Presented for regularly scheduled obstetrical care with symptoms
* \< 18 years old and not emancipated consenting minor
* \< 200/7 weeks of gestation or ≥ 37 weeks of gestation cervix length \> 30 mm
* cervical dilatation \> 3 centimeters
* overt rupture of the fetal membranes (ROM) as indicated by visualized leakage of fluid from the cervical os
* heavy vaginal bleeding
* received tocolytic medications for treatment of threatened preterm delivery prior to collection of the cervicovaginal specimens or cervical length measurements
* suspected placenta previa
* cervical cerclage in place
* a symptom not associated with idiopathic threatened preterm delivery (e.g. trauma)
* digital exam prior to specimen collection

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes